A groundbreaking injectable medication has demonstrated remarkable effectiveness in reducing cholesterol levels, potentially ...

Healthcare professionals often use subcutaneous injections for medications, such as insulin, which need to be absorbed into the bloodstream slowly and steadily. Subcutaneous injections are usually ...

Factor XIIa inhibitor Andembry (garadacimab) has been cleared in the US for use in patients aged 12 and over with HAE, which ...

Celltrion announces US FDA approval of additional presentation of Steqeyma, expanding dosing options for paediatric patients: Incheon, South Korea Tuesday, June 17, 2025, 16:00 Hr ...

Andembry is the first prophylactic therapy for hereditary angioedema to target factor XIIa, inhibiting the top of the ...

Panelists discuss how subcutaneous (SubQ) drug formulations offer practical value by significantly reducing treatment times, easing staffing pressures, and enhancing efficiency in oncology practices, ...

Steqeyma is now supplied as a 45mg/0.5mL solution in a single-dose vial for subcutaneous injection, allowing for weight-based dosing for pediatric patients under 60kg.

Australian biotech CSL has announced that the US Food and Drug Administration (FDA) has approved Andembry (garadacimab-gxii), ...

Celltrion's FDA approval of Steqeyma enhances pediatric psoriasis treatment, offering flexible dosing options for children ...

Bristol Myers Squibb's Opdivo has been approved in a subcutaneous injection formulation by the FDA, making treatment easier for patients and potentially adding years to the product's patent life.

Wegovy (semaglutide) is approved by the U.S. Food and Drug Administration (FDA) for weight loss and weight management in ...